Gad A Marshall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6748244/publications.pdf

Version: 2024-02-01

61945 51562 8,108 131 43 86 citations h-index g-index papers 157 157 157 9658 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. Neuron, 2009, 63, 178-188.	3.8	899
2	Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease. Annals of Neurology, 2016, 79, 110-119.	2.8	778
3	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	4.5	512
4	Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Research and Therapy, 2012, 4, 43.	3.0	402
5	Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 300-308.	0.4	319
6	Amyloidâ€Î² associated cortical thinning in clinically normal elderly. Annals of Neurology, 2011, 69, 1032-1042.	2.8	306
7	Loneliness, depression and cognitive function in older U.S. adults. International Journal of Geriatric Psychiatry, 2017, 32, 564-573.	1.3	269
8	Amyloid- \hat{l}^2 deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 2015, 138, 1023-1035.	3.7	207
9	Positron Emission Tomography Metabolic Correlates of Apathy in Alzheimer Disease. Archives of Neurology, 2007, 64, 1015.	4.9	185
10	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. American Journal of Psychiatry, 2018, 175, 530-537.	4.0	175
11	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193.	2.8	171
12	Subjective Cognitive Concerns and Neuropsychiatric Predictors of ProgressionÂto the Early Clinical Stages ofÂAlzheimer Disease. American Journal of Geriatric Psychiatry, 2014, 22, 1642-1651.	0.6	167
13	Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimer's and Dementia, 2017, 13, 84-100.	0.4	167
14	Interactive Associations of Vascular Risk and \hat{l}^2 -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124.	4.5	165
15	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry, 2016, 73, 1230.	6.0	164
16	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	4.5	142
17	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid \hat{l}^2 . Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
18	Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. Neurodegenerative Disease Management, 2012, 2, 483-491.	1,2	129

#	Article	IF	CITATIONS
19	Neuropathologic Correlates of Apathy in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 144-147.	0.7	128
20	Subjective cognitive concerns, amyloid- \hat{l}^2 , and neurodegeneration in clinically normal elderly. Neurology, 2015, 85, 56-62.	1.5	127
21	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 2015, 84, 2153-2160.	1.5	120
22	Early-Onset Alzheimer's Disease Is Associated With Greater Pathologic Burden. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 29-33.	1.2	108
23	Neuropsychiatric Symptoms and Global Functional Impairment along the AlzheimerÂ's Continuum. Dementia and Geriatric Cognitive Disorders, 2012, 34, 96-111.	0.7	105
24	Long-Term Treatment of Hashimoto's Encephalopathy. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 14-20.	0.9	100
25	Associations of Physical Activity and \hat{l}^2 -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	4.5	97
26	PET staging of amyloidosis using striatum. Alzheimer's and Dementia, 2018, 14, 1281-1292.	0.4	93
27	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2015, 46, 63-73.	1.2	87
28	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. American Journal of Geriatric Psychiatry, 2014, 22, 1168-1179.	0.6	86
29	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology, 2016, 87, 920-926.	1.5	86
30	Vascular Risk and β â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	2.8	75
31	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	2.8	72
32	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. Journal of Alzheimer's Disease, 2017, 59, 975-985.	1.2	70
33	Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Current Alzheimer Research, 2017, 14, 426-440.	0.7	68
34	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 421-432.	1.2	65
35	Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. Current Alzheimer Research, 2015, 12, 493-502.	0.7	62
36	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. NeuroImage: Clinical, 2017, 15, 408-414.	1.4	61

#	Article	IF	CITATIONS
37	Apathy Is Associated With Increased Amyloid Burden in Mild Cognitive Impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25, 302-307.	0.9	56
38	Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. Journal of Psychiatric Research, 2021, 138, 176-185.	1.5	53
39	Heterogeneity in Suspected Non–Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurology, 2016, 73, 1185.	4.5	52
40	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 41, 719-728.	1.2	51
41	Amyloidâ€associated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	1.8	51
42	Apathy is Associated With Lower Inferior Temporal Cortical Thickness in Mild Cognitive Impairment and Normal Elderly Individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e22-e27.	0.9	50
43	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology, 2017, 88, 1759-1767.	1.5	50
44	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 249-260.	1.2	50
45	Neuropathologic Correlates of Activities of Daily Living in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 56-59.	0.6	49
46	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 727-735.	1.2	44
47	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. Journal of Alzheimer's Disease, 2016, 53, 1097-1105.	1.2	44
48	Everyday Cognition Scale Items that Best Discriminate Between and Predict Progression From Clinically Normal to Mild Cognitive Impairment. Current Alzheimer Research, 2014, 11, 853-861.	0.7	44
49	Instrumental Activities of Daily Living Impairment Is Associated with Increased Amyloid Burden. Dementia and Geriatric Cognitive Disorders, 2011, 31, 443-450.	0.7	43
50	Evolution of anosognosia in alzheimer's disease and its relationship to amyloid. Annals of Neurology, 2020, 87, 267-280.	2.8	39
51	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 42, 291-300.	1.2	38
52	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693.	0.6	37
53	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 2015, 85, 48-55.	1.5	36
54	Advance Care Planning in Community-Dwelling Patients With Dementia. Journal of Pain and Symptom Management, 2018, 55, 1105-1112.	0.6	35

#	Article	IF	Citations
55	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2019, 67, 757-768.	1.2	32
56	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.2	30
57	Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. American Journal of Geriatric Psychiatry, 2022, 30, 119-147.	0.6	28
58	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 14.	3.0	26
59	The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 896-904.	0.6	23
60	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. EClinicalMedicine, 2022, 45, 101343.	3.2	21
61	Late-onset unexplained epilepsy: What are we missing?. Epilepsy and Behavior, 2019, 99, 106478.	0.9	19
62	Association of cortical microstructure with amyloid- \hat{l}^2 and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Molecular Psychiatry, 2021, 26, 7813-7822.	4.1	17
63	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
64	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. journal of prevention of Alzheimer's disease, The, 2015, 2, 242-253.	1.5	14
65	Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study. Current Alzheimer Research, 2018, 15, 1231-1243.	0.7	13
66	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12118.	1.2	12
67	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiology of Aging, 2016, 40, 61-67.	1.5	11
68	SIST-M-IR Activities of Daily Living Items that Best Discriminate Clinically Normal Elderly from those with Mild Cognitive Impairment. Current Alzheimer Research, 2014, 11, 785-791.	0.7	11
69	Financial Capacity and Regional Cerebral Tau in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2021, 79, 1133-1142.	1.2	10
70	Affective symptoms and regional cerebral tau burden in earlyâ€stage Alzheimer's disease. International Journal of Geriatric Psychiatry, 2021, 36, 1050-1058.	1.3	10
71	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimer's Research and Therapy, 2019, 11, 4.	3.0	9
72	The neurophysiology and seizure outcomes of late onset unexplained epilepsy. Clinical Neurophysiology, 2020, 131, 2667-2672.	0.7	9

#	Article	IF	Citations
73	Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. SLEEP Advances, 2021, 2, zpab015.	0.1	9
74	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. NeuroImage: Clinical, 2018, 17, 388-396.	1.4	8
75	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. journal of prevention of Alzheimer's disease, The, 2017, 4, 81-86.	1.5	8
76	Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive Decline From Clinical Notes in Electronic Health Records. JAMA Network Open, 2021, 4, e2135174.	2.8	8
77	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332.	0.9	7
78	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. Journal of Alzheimer's Disease, 2019, 68, 1161-1170.	1.2	5
79	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
80	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE., 2014, 10, P365-P365.		1
81	IC-P-117: AMYLOID-B DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P65-P66.		1
82	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
83	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals., 2015, 11, P265-P265.		1
84	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly., 2015, 11, P267-P267.		1
85	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimer's Disease. , 2016, 12, P373-P373.		1
86	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment., 2016, 12, P36-P37.		1
87	O4â€06â€06: The Impact of Anosognosia and Anosodiaphoria on the Prediction of Progression from Mild Cognitive Impairment to Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P346.	0.4	1
88	[P3â€"376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P1103.	0.4	1
89	P3â€430: INFERIOR AND MEDIAL TEMPORAL TAU AND CORTICAL AMYLOID ARE ASSOCIATED WITH DAILY FUNCTIONAL IMPAIRMENT ACROSS THE AD SPECTRUM. Alzheimer's and Dementia, 2018, 14, P1275.	0.4	1
90	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1

#	Article	IF	Citations
91	Dementia knowledge and associated demographic factors within a registry sample. Alzheimer's and Dementia, 2020, 16, e046177.	0.4	1
92	Longitudinal associations of regional cortical tau and apathy in mild cognitive impairment and Alzheimer's disease dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2021, 17, .	0.4	1
93	Neuropsychiatric Evaluation in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 53-61.	1.0	0
94	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		0
95	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
96	P2-154: SUBSYNDROMAL DEPRESSION AND ALZHEIMER'S DISEASE BIOMARKERS IN COGNITIVELY NORMAL ELDERLY., 2014, 10, P527-P528.		0
97	IC-P-152: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		0
98	O3-10-06: AMYLOID- \hat{l}^2 DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P230-P230.		0
99	P1-301: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P422-P422.		0
100	IC-02-01: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P4-P4.		0
101	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment., 2015, 11, P53-P53.		0
102	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0
103	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
104	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals., 2015, 11, P675-P676.		0
105	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals., 2015, 11, P102-P103.		0
106	O2-11-06: Reciprocal relations of loneliness and cognitive function in older u.s. adults., 2015, 11, P201-P202.		0
107	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		0
108	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.4	0

#	Article	IF	Citations
109	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration., 2016, 12, P773-P774.		0
110	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.4	0
111	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		O
112	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.4	0
113	[P4â€"243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P1369.	0.4	O
114	[ICâ€Pâ€089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMA DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P72.	L _{0.4}	0
115	[P1–256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P347.	0.4	O
116	P1â€327: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P417.	0.4	0
117	P3â€290: AMYLOID PATHOLOGY EXPLAINS UNAWARENESS OF MEMORY DEFICITS ABOVE AND BEYOND CORTICAL THICKNESS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	O
118	P1â€627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€AD COHORT. Alzheimer's and Dementia, 2018, 14, P581.	S 0.4	0
119	ICâ€P‶39: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITI DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	VE 0.4	O
120	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TOÂ <i>IN VIVO</i> CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
121	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED βâ€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	O
122	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e038867.	0.4	0
123	Depressive symptoms are associated with hippocampal neurodegeneration in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046495.	0.4	O
124	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e046549.	0.4	0
125	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e047321.	0.4	O
126	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
127	Trajectories of selfâ€rated concerns in individuals developing cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	O
128	Greater psychological resilience during the COVIDâ€19 pandemic is associated with lower tau burden in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
129	Association between the Harvard automated phone task and Alzheimer's disease pathology in clinically normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	O
130	Resilience and perceived stress in cognitively normal older adults during the COVIDâ \in 19 pandemic. Alzheimer's and Dementia, 2021, 17, .	0.4	0
131	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0